Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9H4B0
UPID:
OSGL1_HUMAN
Alternative names:
N6-L-threonylcarbamoyladenine synthase; O-sialoglycoprotein endopeptidase-like protein 1; t(6)A37 threonylcarbamoyladenosine biosynthesis protein OSGEPL1; tRNA threonylcarbamoyladenosine biosynthesis protein OSGEPL1
Alternative UPACC:
Q9H4B0; Q96EV9; Q96NH5
Background:
The tRNA N6-adenosine threonylcarbamoyltransferase, mitochondrial, known by alternative names such as N6-L-threonylcarbamoyladenine synthase and OSGEPL1, plays a crucial role in mitochondrial tRNA modification. It is essential for the formation of a threonylcarbamoyl group on adenosine at position 37 in mitochondrial tRNAs that read codons beginning with adenine, facilitating mitochondrial genome maintenance.
Therapeutic significance:
Understanding the role of tRNA N6-adenosine threonylcarbamoyltransferase could open doors to potential therapeutic strategies.